Polyphor receives up to 18 million dollars for development of antibiotics
The Allschwil-based company Polyphor has received a second funding award from the global consortium CARB-X to combat antimicrobial resistance. Polyphor will be provided with initial funding of up to 2.62 million US dollars for its innovative antibiotics program. A maximum of 15.82 million dollars has been earmarked for later milestones.
As the life sciences company Polyphor wrote in a press release, this funding is the second major support by the global public-private consortium CARB-X and follows a previous grant in 2019. This partnership led by Boston University is dedicated to supporting the development of antibacterial products, to diagnose, prevent and treat drug-resistant infections. Polyphor is located in Allschwil in the canton of Basel-Landschaft. The Basel area is known as a leading center for combatting antimicrobial resistance.
This award will support the development of the novel class of antibiotics discovered by Polyphor and the University of Zurich. These show potent and specific antimicrobial activity against Enterobacteriaceae, including extremely drug resistant strains. They are among the priority-1 pathogens, as classified by the World Health Organization.
CARB-X will provide Polyphor with initial funding of up to 2.62 million US Dollars to complete the hit-to-lead stage. Up to 15.82 million dollars will additionally be granted if certain project milestones are met.
“CARB-X fosters the best science and most promising early development R&D-projects in the world,” explains Polyphor CEO Gökhan Batur in the press release. “This second award is a strong validation of our innovative antibiotic platform and an important milestone in the implementation of our renewed strategy in this field presented earlier this year.”
“Serious infections are a global health threat, due in part to the emergence of drug-resistant bacteria for which we do not have therapies,” said Erin Duffy, R&D Chief of CARB-X. “Polyphor’s project enriches the pool of novel approaches to deliver a therapeutic that can treat infections caused by multidrug-resistant Gram-negative pathogens for which we have few options. It is in the early stages of development, and if successful and approved, it could potentially change the way these life-threatening infections are treated and save lives.”
Share this article
You may also be interested in
Evolva launches new line for manufacturers of personal care products
Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...Read More
Record figure for startups in the Basel Area
Basel Area Business & Innovation has supported a record number of 96 company startups in 2022. The number of settlements...Read More
Noema Pharma raises 103 million Swiss francs from investors
Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....Read More
Why CDMO companies choose the Basel Area as their location
Originally, this article was published by the US magazine Outsourced Pharma under the title "Why Location Matters". The article highlights...Read More
Basel still the most attractive small city for business in Europe
As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...Read More
Ariceum Therapeutics establishes subsidiary in Basel
The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...Read More